Neoadjuvant Dovitinib in Early- and Intermediate-Stage Hepatocellular Carcinoma

This letter to the editor comments on recently reported results of a phase II study of dovitinib therapy for hepatocellular carcinoma

Detalles Bibliográficos
Autores principales: Rizzo, Alessandro, Dalia Ricci, Angela, Brandi, Giovanni
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9732236/
https://www.ncbi.nlm.nih.gov/pubmed/35993601
http://dx.doi.org/10.1093/oncolo/oyac168
_version_ 1784846082063204352
author Rizzo, Alessandro
Dalia Ricci, Angela
Brandi, Giovanni
author_facet Rizzo, Alessandro
Dalia Ricci, Angela
Brandi, Giovanni
author_sort Rizzo, Alessandro
collection PubMed
description This letter to the editor comments on recently reported results of a phase II study of dovitinib therapy for hepatocellular carcinoma
format Online
Article
Text
id pubmed-9732236
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-97322362022-12-13 Neoadjuvant Dovitinib in Early- and Intermediate-Stage Hepatocellular Carcinoma Rizzo, Alessandro Dalia Ricci, Angela Brandi, Giovanni Oncologist Letter to the Editor This letter to the editor comments on recently reported results of a phase II study of dovitinib therapy for hepatocellular carcinoma Oxford University Press 2022-08-22 /pmc/articles/PMC9732236/ /pubmed/35993601 http://dx.doi.org/10.1093/oncolo/oyac168 Text en © The Author(s) 2022. Published by Oxford University Press. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Letter to the Editor
Rizzo, Alessandro
Dalia Ricci, Angela
Brandi, Giovanni
Neoadjuvant Dovitinib in Early- and Intermediate-Stage Hepatocellular Carcinoma
title Neoadjuvant Dovitinib in Early- and Intermediate-Stage Hepatocellular Carcinoma
title_full Neoadjuvant Dovitinib in Early- and Intermediate-Stage Hepatocellular Carcinoma
title_fullStr Neoadjuvant Dovitinib in Early- and Intermediate-Stage Hepatocellular Carcinoma
title_full_unstemmed Neoadjuvant Dovitinib in Early- and Intermediate-Stage Hepatocellular Carcinoma
title_short Neoadjuvant Dovitinib in Early- and Intermediate-Stage Hepatocellular Carcinoma
title_sort neoadjuvant dovitinib in early- and intermediate-stage hepatocellular carcinoma
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9732236/
https://www.ncbi.nlm.nih.gov/pubmed/35993601
http://dx.doi.org/10.1093/oncolo/oyac168
work_keys_str_mv AT rizzoalessandro neoadjuvantdovitinibinearlyandintermediatestagehepatocellularcarcinoma
AT daliaricciangela neoadjuvantdovitinibinearlyandintermediatestagehepatocellularcarcinoma
AT brandigiovanni neoadjuvantdovitinibinearlyandintermediatestagehepatocellularcarcinoma

Ejemplares similares